The relationship of hormone-positive status in breast cancer patients with carriage of a mutation in the BRCA2 gene

This review focuses on breast cancer associated with mutations in the BRCA1 and BRCA2 genes, as well as the influence of the hormone-receptor status of the tumor on clinical characteristics and prognosis. Breast cancer remains the leading form of cancer among women worldwide. The need to find effective therapies for breast cancer, especially in patients with genetic mutations, is becoming increasingly evident. BRCA1 and BRCA2 are the genes in which mutations are most commonly associated with a predisposition to developing breast cancer. Women who inherit these mutations face a high cumulative risk of disease, reaching 55-65% before age 70 for the BRCA1 gene and 45-55% for the BRCA2 gene. The association of hormone-positive tumor status with carrying a mutation in the BRCA2 gene is interesting. In patients with BRCA2 mutations, receptor-positive tumor status may have an adverse effect on the prognosis of breast cancer patients. Mutations in BRCA1/2 genes and hormone receptor status play a key role in predicting the outcomes of breast cancer, highlighting the importance of early diagnosis and personalized treatment strategies to improve survival and disease control. This review focuses on breast cancer associated with mutations in the BRCA1 and BRCA2 genes and the impact of tumor hormonereceptor status on clinical characteristics and prognosis.